On the other hand, acetylation enhances SRBP activity by increasing its stability and recruitment to its lipogenic target promoters, which favours lipogenesis and contribute to fatty liver disease (hepatosteatosis), a condition associated with obesity and insulin resistance63. Here, SIGMAR1 is linked to fatty liver disease.